INFORMAZIONI SU QUESTO EPISODIO
While the cell and gene therapy space represents one of the most exciting therapeutic frontiers in modern biopharma by offering highly personalized, transformative treatments, the sector still faces significant hurdles before it can achieve widespread commercialization. From steep manufacturing costs and a lack of standardization to persistent inefficiencies in scaling production, the road to maturity remains complex.
In this episode of Off Script: A Pharma Manufacturing Podcast, we spoke with Sharon Anderson, VP of Scientific Affairs, Alliance for Regenerative Medicine, about what’s driving progress in CGT manufacturing and where the industry is still lagging.
Inglese
Stati Uniti
TRASCRIZIONE 🔗
Are you the producer of this podcast?
Add a podcast transcript
Need Audio-to-Text?
Transcribe with Listen411 in Just 60 Seconds
CERCA TRA GLI EPISODI PASSATI
Cerca gli episodi passati di Off Script: A Pharma Manufacturing Podcast.
ALTRI EPISODI IN QUESTO PODCAST
Biopharmaceutical manufacturing processes are becoming more complex, prompting manufacturers to evaluate filtration based on its impact across the entire process rather than as a standalone unit operation. Filtration decisions can influence everything from system footprint and flow performance to i…
The demands on pharmaceutical manufacturing quality teams are growing as they manage larger volumes of data driven by increasingly complex therapies and evolving regulatory expectations. In response, artificial intelligence is emerging as a powerful tool to help quality professionals synthesize inf…
Single-use technologies have reshaped biopharma manufacturing facility design, capacity strategy, and flexibility over the past decade. The industry has expanded with a growing range of targeted therapies and emerging modalities, which has led to manufacturers adopting single-use systems to meet de…
Radiopharmaceuticals are a rapidly growing area of oncology, fueled by advances in targeted therapies and expanding product pipelines. But bringing these therapies from development to commercialization presents unique manufacturing challenges, from isotope supply and specialized GMP facilities to t…
Sterile ophthalmic manufacturing is facing growing demand as more preservative-free therapies move through development, while manufacturers also contend with increasingly stringent expectations around contamination control, inspection, and quality. Blow-fill-seal (BFS) technology offers a closed, h…
Dichiarazione di non responsabilità: Il podcast e la grafica incorporati in questa pagina provengono da Pharma Manufacturing, che è di proprietà del suo proprietario e non è affiliato o approvato da Listen Notes, Inc.
MODIFICA
Grazie, ci hai aiutato a mantenere aggiornato il database dei podcast.
